Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (231-240 of 368) with videos related to

Pageof 37
Sort By:
Plos One|July 21, 2015
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering AnalysisFrançois M J Lamoury, Brendan Jacka, Sofia Bartlett, et al.
Journal of Hepatology|February 13, 2016
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
Journal of Viral Hepatitis|August 9, 2019
Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling studyAdam Trickey, Hannah Fraser, Aaron G Lim, et al.
Plos One|November 19, 2013
High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort studyRachel Sacks-Davis, Campbell K Aitken, Peter Higgs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
The Lancet. Psychiatry|February 28, 2021
Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysisJack Stone, Louisa Degenhardt, Jason Grebely, et al.
Journal of Viral Hepatitis|April 14, 2019
Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness studySahar Bajis, Jason Grebely, Lucy Cooper, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D studyMarianne Martinello, Sanjay Bhagani, David Shaw, et al.
Viruses|August 28, 2021
SHARED: An International Collaboration to Unravel Hepatitis C ResistanceAnita Y M Howe, Francesca Ceccherini-Silberstein, Julia Dietz, et al.
The International Journal on Drug Policy|April 12, 2024
Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage studyHeather Valerio, Alison D Marshall, Anna Conway, et al.
Pageof 37

Showing results (231-240 of 368) with videos related to

Sort By:
Pageof 37
Plos One|July 21, 2015
The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering AnalysisFrançois M J Lamoury, Brendan Jacka, Sofia Bartlett, et al.
Journal of Hepatology|February 13, 2016
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
Journal of Viral Hepatitis|August 9, 2019
Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling studyAdam Trickey, Hannah Fraser, Aaron G Lim, et al.
Plos One|November 19, 2013
High rates of hepatitis C virus reinfection and spontaneous clearance of reinfection in people who inject drugs: a prospective cohort studyRachel Sacks-Davis, Campbell K Aitken, Peter Higgs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2016
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION TrialsJason Grebely, Stefan Mauss, Ashley Brown, et al.
The Lancet. Psychiatry|February 28, 2021
Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysisJack Stone, Louisa Degenhardt, Jason Grebely, et al.
Journal of Viral Hepatitis|April 14, 2019
Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness studySahar Bajis, Jason Grebely, Lucy Cooper, et al.
JHEP Reports : Innovation in Hepatology|September 29, 2023
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D studyMarianne Martinello, Sanjay Bhagani, David Shaw, et al.
Viruses|August 28, 2021
SHARED: An International Collaboration to Unravel Hepatitis C ResistanceAnita Y M Howe, Francesca Ceccherini-Silberstein, Julia Dietz, et al.
The International Journal on Drug Policy|April 12, 2024
Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage studyHeather Valerio, Alison D Marshall, Anna Conway, et al.
Pageof 37